268 related articles for article (PubMed ID: 16264047)
21. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
Fruhwald FM; Kjellström B; Perthold W; Wonisch M; Maier R; Klein W
J Heart Lung Transplant; 2005 May; 24(5):631-4. PubMed ID: 15896766
[TBL] [Abstract][Full Text] [Related]
22. [Combination therapy in patients with pulmonary arterial hypertension].
Ewert R; Opitz CF; Schäper C; Gläser S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
[TBL] [Abstract][Full Text] [Related]
23. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A
J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621
[TBL] [Abstract][Full Text] [Related]
24. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.
Barnett CF; Bonura EJ; Nathan SD; Ahmad S; Shlobin OA; Osei K; Zaiman AL; Hassoun PM; Moller DR; Barnett SD; Girgis RE
Chest; 2009 Jun; 135(6):1455-1461. PubMed ID: 19118270
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of idiopathic pulmonary arterial hypertension].
Andreassen AK; Gude E; Solberg OG; Ueland T
Tidsskr Nor Laegeforen; 2011 Jul; 131(13-14):1285-8. PubMed ID: 21725387
[TBL] [Abstract][Full Text] [Related]
27. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
Sitbon O; Jaïs X; Savale L; Cottin V; Bergot E; Macari EA; Bouvaist H; Dauphin C; Picard F; Bulifon S; Montani D; Humbert M; Simonneau G
Eur Respir J; 2014 Jun; 43(6):1691-7. PubMed ID: 24627535
[TBL] [Abstract][Full Text] [Related]
28. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
[TBL] [Abstract][Full Text] [Related]
29. Inhaled nitric oxide plus iloprost in the setting of post-left assist device right heart dysfunction.
Antoniou T; Prokakis C; Athanasopoulos G; Thanopoulos A; Rellia P; Zarkalis D; Kogerakis N; Koletsis EN; Bairaktaris A
Ann Thorac Surg; 2012 Sep; 94(3):792-8. PubMed ID: 22727248
[TBL] [Abstract][Full Text] [Related]
30. Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study.
Gall H; Sommer N; Milger K; Richter MJ; Voswinckel R; Bandorski D; Seeger W; Grimminger F; Ghofrani HA
BMC Pulm Med; 2016 Jan; 16():5. PubMed ID: 26753921
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report.
Mogollón MV; Lage E; Cabezón S; Hinojosa R; Ballesteros S; Aranda A; Sobrino JM; Ordóñez A
Transplant Proc; 2006 Oct; 38(8):2522-3. PubMed ID: 17097987
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
Halank M; Kolditz M; Miehlke S; Schiemanck S; Schmeisser A; Hoeffken G
Wien Med Wochenschr; 2005 Aug; 155(15-16):376-80. PubMed ID: 16160926
[TBL] [Abstract][Full Text] [Related]
33. When to initiate intravenous therapy and/or refer.
Champion HC
Am J Cardiol; 2013 Apr; 111(8 Suppl):21C-4C. PubMed ID: 23558027
[TBL] [Abstract][Full Text] [Related]
34. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
[TBL] [Abstract][Full Text] [Related]
35. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
[TBL] [Abstract][Full Text] [Related]
36. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.
Opitz CF; Wensel R; Winkler J; Halank M; Bruch L; Kleber FX; Höffken G; Anker SD; Negassa A; Felix SB; Hetzer R; Ewert R
Eur Heart J; 2005 Sep; 26(18):1895-902. PubMed ID: 15888496
[TBL] [Abstract][Full Text] [Related]
38. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic treatment for pulmonary arterial hypertension.
Sastry BK
Curr Opin Cardiol; 2006 Nov; 21(6):561-8. PubMed ID: 17053404
[TBL] [Abstract][Full Text] [Related]
40. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
